[CLSTR]
< Back to all clusters
[HEALTH] · United States · 7 sources

started · updated

Part of situation: GLP-1 drugs: clinical trends, safety, and market shifts (314 clusters)

GLP-1 drugs face scrutiny over cardiovascular claims, doping concerns, and blindness lawsuits

GLP-1 drugs Ozempic Mounjaro weight-loss medication medical litigation

Novo Nordisk has reported findings from a real-world study involving 636,525 adults with type 2 diabetes. The study suggests that patients who increased their Ozempic dose from 1 mg to 2 mg experienced a 6% lower risk of major adverse cardiovascular events compared to those who switched to Eli Lilly’s Mounjaro.

While the drugs are driving massive market growth, they are facing increasing scrutiny. The World Anti-Doping Agency is monitoring semaglutide and tirzepatide due to concerns that athletes may use them for weight loss to gain performance advantages in endurance sports.

Additionally, the manufacturers are facing significant legal challenges in the United States. More than 200 federal lawsuits have been filed by users of Ozempic, Wegovy, and Mounjaro, alleging that the medications can cause permanent vision loss or blindness through a condition known as non-arteritic anterior ischemic optic neuropathy (NAION).

Entities

Eli Lilly · Mounjaro · Novo Nordisk · Ozempic · World Anti-Doping Agency

Claims

What the coverage asserts, and how many sources carry each claim.

  • [○ 1 SOURCE] Over 200 federal lawsuits in the United States allege that GLP-1 drugs like Ozempic and Mounjaro cause permanent vision loss or blindness. www.youweekly.gr
  • [○ 1 SOURCE] Patients escalating Ozempic from 1 mg to 2 mg saw a 6% lower risk of major adverse cardiovascular events compared to those switching to Mounjaro doses up to 15 mg. srnnews.com
  • [○ 1 SOURCE] A real-world study found Ozempic users with escalated doses had a lower risk of major cardiovascular events than those switching to Mounjaro. srnnews.com
  • [○ 1 SOURCE] An analysis of 636,525 adults showed 67.2% remained on 1 mg of Ozempic within 365 days, while 29.2% either increased to 2 mg or switched to Mounjaro. srnnews.com
  • [○ 1 SOURCE] The World Anti-Doping Agency is monitoring semaglutide and tirzepatide due to concerns regarding their use in sports. www2.u-trail.com
  • [○ 1 SOURCE] Lawsuits link GLP-1 drugs to non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden vision loss. www.youweekly.gr

Sources

Anvisa libera emissão online de receitas amarelas e azuis, entenda o que muda na farmácia [omatogrosso.com]
Saiba como o Mounjaro desbancou o Ozempic e concentrou 70% do mercado de GLP-1 no Brasil [revistadafarmacia.com.br]
Δικαστικός «πόλεμος» για τις ενέσεις αδυνατίσματος: Αγωγές για μόνιμη τύφλωση από Ozempic και Mounjaro! [www.youweekly.gr]
Ozempic, Wegovy, Mounjaro : pourquoi l’antidopage commence à surveiller les médicaments amaigrissants [www2.u-trail.com]
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro [srnnews.com]
Your Body Already Makes What’s in Ozempic. Switch It Back On. [www.mindvalley.com]
Troca de caneta por comprimido do Wegovy mantém perda de peso e Novo ganha munição [exame.com]